LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cardiovascular Risk Predicted by Test Measuring HDL Proteins

By LabMedica International staff writers
Posted on 09 Dec 2014
Print article
Image: The composition of High-Density Lipoprotein Cholesterol (Photo courtesy of the University of California Davis).
Image: The composition of High-Density Lipoprotein Cholesterol (Photo courtesy of the University of California Davis).
A new laboratory test has been developed that measures the presence of certain proteins in the High-Density Lipoprotein complex that can lead to an increased risk of cardiovascular disease and mortality.

High-Density Lipoprotein (HDL) is a class of proteins that plays a key role in the body's metabolism of cholesterol and HDL causes the cholesterol to be transported to the liver, where it is broken down and this gives rise to the popular name for HDL of “good cholesterol.” HDL is made up of only around 20% cholesterol and over 50% of HDL is made up of different proteins.

Scientists at the Medical University of Vienna (Austria) measured the concentrations of HDL-associated serum amyloid A (SAA) and surfactant protein B (SP-B) in 1,152 patients with type 2 diabetes mellitus on hemodialysis participating in The German Diabetes Dialysis Study who were randomly assigned to double-blind treatment of 20 mg atorvastatin daily or matching placebo. The association of SAA (HDL) and SP-B (HDL) with cardiovascular outcomes was assessed in multivariate regression models adjusted for known clinical risk factors.

High levels of SAA in the HDL were associated with an increased occurrence of heart attacks, while high levels of SP-B in the HDL acted as a marker for a generally increased risk of mortality. This discovery could change the evaluation of HDL. Clinical practice currently only measures the amount of cholesterol in the HDL (known as the HDL-C) and from which the protective effect against future cardiovascular disease is derived. This relationship may hold true for the healthy population. More recent studies have shown, however, that in many chronic diseases such as coronary heart disease, diabetes mellitus or in patients receiving dialysis, the quantity of HDL-C in the blood cannot be used as a prognostic marker.

The authors concluded that the HDL-C value continues to remain important, however the new test will also in future allow a much more precise risk prediction for cardiovascular diseases, allowing therapy to be commenced much earlier, for example through a modified lifestyle, in order to decisively improve the overall prognosis. In patients with diabetes on hemodialysis, SAA (HDL) and SP-B (HDL) were related to cardiac events and all-cause mortality, respectively, and they were independent of HDL cholesterol. The study was published in the November 2014 issue of the Clinical Journal of the American Society of Nephrology.

Related Links:

Medical University of Vienna


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more